Two pharmaceutical cases highlight recent developments in Canadian patent law relating to duty of candour during patent prosecution and patent claim construction, says Katie Wang.
Two pharmaceutical cases highlight recent developments in Canadian patent law relating to duty of candour during patent prosecution and patent claim construction, says Katie Wang.
Duty of candour
A recent case from the Federal Court in Canada has highlighted the importance of duty of candour during prosecution and closely scrutinising the file wrapper in assessing patent validity.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
Canada, Federal Court, patent validity, pharmaceuticals
